…
Polaryx Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of disease-modifying therapies for rare and pediatric lysosomal storage disorders in the United States. Its pipeline includes PLX-100, a preclinical stage orally administrable combination therapy; PLX-200, a repurposed oral small molecule for the treatment of LSDs; PLX-300, a preclinical stage orally administrable combination therapy; and PLX-400, a preclinical stage novel gene therapy candidate. The company was founded in 2014 and is based in Paramus, New Jersey.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Polaryx Therapeutics (NASDAQ: PLYX) is a clinical-stage biopharmaceutical company developing therapeutics; long-term growth drivers include advancement of its clinical pipeline, regulatory milestones, and potential strategic partnerships that could support commercialization. Investors may find the company attractive because clinical progress and proprietary assets may benefit valuation if trials and approvals proceed.
Important risks include trial failures or regulatory delays, ongoing financing needs, limited or no product revenue, and intellectual property or operational uncertainties.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Type | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 |
| Income before tax | -8.98M | -30.36M | -3.78M |
| Net income | -8.98M | -30.36M | -3.78M |
| Selling general administrative | 1.55M | 1.54M | 1.01M |
| Ebitda | -8.98M | -30.36M | -3.78M |
| Operating income | -7.82M | -4.35M | -3.78M |
| Other operating expenses | 7.82M | 4.35M | 3.78M |
| Total revenue | 0.00M | 0.00M | 0.00M |
| Total operating expenses | 7.82M | 4.35M | 3.78M |
| Total other income expense net | -1.16M | -26.00M | 0.00M |
| Net income from continuing ops | -8.98M | -30.36M | -3.78M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Type | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 |
| Total assets | 5.42M | 5.00M | 2.31M |
| Other current assets | 0.03M | 0.38M | 2.31M |
| Total liab | 0.85M | 0.29M | 1.04M |
| Total stockholder equity | 4.57M | 4.71M | 1.28M |
| Other current liab | 0.14M | 0.22M | 0.44M |
| Common stock | 0.01M | 0.02M | 0.00M |
| Capital stock | 0.01M | 0.02M | 0.00M |
| Retained earnings | -99.64M | -90.65M | -60.29M |
| Cash | 5.14M | 4.62M | 0.00M |
| Total current liabilities | 0.60M | 0.29M | 1.04M |
| Net debt | -5.14M | -4.62M | 0.13M |
| Short term debt | - | - | 0.13M |
| Short long term debt | - | - | 0.13M |
| Short long term debt total | - | - | 0.13M |
| Other stockholder equity | 104.19M | 95.35M | 61.57M |
| Total current assets | 5.17M | 5.00M | 2.31M |
| Accounts payable | 0.47M | 0.07M | 0.47M |
| Non current assets total | 0.25M | 0.00M | 0.00M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Type | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 |
| Net borrowings | 0.00M | -0.13M | 0.13M |
| Total cash from financing activities | 4.47M | 7.19M | 0.13M |
| Net income | -8.98M | -30.36M | -3.78M |
| Change in cash | 0.52M | 4.62M | -0.04M |
| Begin period cash flow | 4.62M | 0.00M | 0.05M |
| End period cash flow | 5.14M | 4.62M | 0.00M |
| Total cash from operating activities | -3.94M | -2.57M | -0.17M |
| Issuance of capital stock | 4.49M | 7.32M | 0.00M |
| Capital expenditures | 0.00M | 0.00M | 0.00M |
| Change in working capital | 0.32M | -0.62M | 0.37M |
| Stock based compensation | 4.72M | 2.40M | 3.24M |
| Other non cash items | 4.72M | 26.00M | - |
| Free cash flow | -3.94M | -2.57M | -0.17M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
|---|---|---|---|---|---|---|
| PLYX Polaryx Therapeutics, Inc. Common Stock |
-0.11 5.85% |
1.77 | - | - | - | 9.30 |
| NVO Novo Nordisk A/S |
0.98 2.41% |
41.63 | 41.58 | 31.15 | 2.13 | 32.99 |
| VRTX Vertex Pharmaceuticals Inc |
-4.02 0.74% |
538.60 | 30.22 | 24.27 | 10.36 | 6.50 |
| REGN Regeneron Pharmaceuticals Inc |
4.28 0.45% |
955.47 | 29.07 | 20.12 | 7.57 | 3.82 |
| ARGNF argenx SE |
64.70 7.19% |
965.00 | 45.77 | 31.25 | 13.84 | 7.12 |
Polaryx Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of disease-modifying therapies for rare and pediatric lysosomal storage disorders in the United States. Its pipeline includes PLX-100, a preclinical stage orally administrable combination therapy; PLX-200, a repurposed oral small molecule for the treatment of LSDs; PLX-300, a preclinical stage orally administrable combination therapy; and PLX-400, a preclinical stage novel gene therapy candidate. The company was founded in 2014 and is based in Paramus, New Jersey.
| Name | Title | Year Born |
|---|---|---|
| Mr. Alex Yang J.D., L.L.M. | CEO & Chair of Board | 1970 |
| Mr. G. Michael Landis CPA | CFO & Director | 1966 |
| Mr. Andrew John O | Chief Investment Officer | 1973 |
| Dr. Shrijay Vijayan M.B.A., Ph.D. | Chief Scientific & Business Development Officer | 1968 |
| Mr. Wuxin Zhu P.M.P., Ph.D. | Chief Chemistry, Manufacturing & Controls Officer | 1980 |
| Dr. Ralph William Charlton III, M.D. | Chief Medical Officer | 1970 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.